198 related articles for article (PubMed ID: 11095407)
1. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in advanced melanoma.
Mouawad R; Khayat D; Soubrane C
Melanoma Res; 2000 Oct; 10(5):461-7. PubMed ID: 11095407
[TBL] [Abstract][Full Text] [Related]
2. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
[TBL] [Abstract][Full Text] [Related]
3. Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus.
Vincent FB; Kandane-Rathnayake R; Koelmeyer R; Harris J; Hoi AY; Mackay F; Morand EF
Lupus Sci Med; 2020 Jun; 7(1):. PubMed ID: 32546562
[TBL] [Abstract][Full Text] [Related]
4. Increased circulating levels of soluble Fas ligand are correlated with disease activity in patients with fibrosing lung diseases.
Kuwano K; Maeyama T; Inoshima I; Ninomiya K; Hagimoto N; Yoshimi M; Fujita M; Nakamura N; Shirakawa K; Hara N
Respirology; 2002 Mar; 7(1):15-21. PubMed ID: 11896896
[TBL] [Abstract][Full Text] [Related]
5. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure.
Nishigaki K; Minatoguchi S; Seishima M; Asano K; Noda T; Yasuda N; Sano H; Kumada H; Takemura M; Noma A; Tanaka T; Watanabe S; Fujiwara H
J Am Coll Cardiol; 1997 May; 29(6):1214-20. PubMed ID: 9137215
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of a combination of soluble Fas and soluble Fas ligand in the serum of patients with Ta bladder cancer.
Mizutani Y; Yoshida O; Ukimura O; Kawauchi A; Bonavida B; Miki T
Cancer Biother Radiopharm; 2002 Oct; 17(5):563-7. PubMed ID: 12470426
[TBL] [Abstract][Full Text] [Related]
7. Circulating soluble Fas ligand correlates with disease activity in Graves' hyperthyroidism.
Wang CY; Zhong WB; Chang TC; Tsai YF
Metabolism; 2002 Jun; 51(6):769-73. PubMed ID: 12037733
[TBL] [Abstract][Full Text] [Related]
8. Examination of soluble Fas (sFas) and soluble Fas ligand (sFasL) in patients with burns.
Yamada Y; Endo S; Nakae H; Makabe H; Sato N; Wakabayashi G; Kitamura M; Inada K; Sato S
Burns; 2003 Dec; 29(8):799-802. PubMed ID: 14636754
[TBL] [Abstract][Full Text] [Related]
9. Fas/Fas-Ligand pathway is impaired in patients with type 2 diabetes. Influence of hypertension and insulin resistance.
Cosson E; Bringuier AF; Paries J; Guillot R; Vaysse J; Attali JR; Feldmann G; Valensi P
Diabetes Metab; 2005 Feb; 31(1):47-54. PubMed ID: 15803113
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of HBxAg in hepatocellular carcinoma and its relationship with Fas/FasL system.
Wang XZ; Chen XC; Chen YX; Zhang LJ; Li D; Chen FL; Chen ZX; Chen HY; Tao QM
World J Gastroenterol; 2003 Dec; 9(12):2671-5. PubMed ID: 14669310
[TBL] [Abstract][Full Text] [Related]
11. Soluble form of fas and fas ligand in BAL fluid from patients with pulmonary fibrosis and bronchiolitis obliterans organizing pneumonia.
Kuwano K; Kawasaki M; Maeyama T; Hagimoto N; Nakamura N; Shirakawa K; Hara N
Chest; 2000 Aug; 118(2):451-8. PubMed ID: 10936140
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinases and soluble Fas/FasL system as novel regulators of apoptosis in children and young adults on chronic dialysis.
Musiał K; Zwolińska D
Apoptosis; 2011 Jul; 16(7):653-9. PubMed ID: 21516345
[TBL] [Abstract][Full Text] [Related]
13. Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases.
Nozawa K; Kayagaki N; Tokano Y; Yagita H; Okumura K; Hasimoto H
Arthritis Rheum; 1997 Jun; 40(6):1126-9. PubMed ID: 9182923
[TBL] [Abstract][Full Text] [Related]
14. Plasma soluble fas and soluble fas ligand in chronic glomerulonephritis.
Sano H; Asano K; Minatoguchi S; Hiraoka J; Fujisawa K; Nishigaki K; Yasuda N; Kumada H; Takemura M; Ohashi H; Seishima M; Fujiwara T; Fujiwara H
Nephron; 1998 Oct; 80(2):153-61. PubMed ID: 9736812
[TBL] [Abstract][Full Text] [Related]
15. The evaluation of soluble Fas and soluble Fas ligand levels of bronchoalveolar lavage fluid in lung cancer patients.
Erdoğan B; Uzaslan E; Budak F; Karadağ M; Ediger D; Oral B; Göral G; Ege E; Gözü O
Tuberk Toraks; 2005; 53(2):127-31. PubMed ID: 16100648
[TBL] [Abstract][Full Text] [Related]
16. Soluble Fas/FasLare elevated in the serum and cerebrospinal fluid of patients with neurocysticercosis.
Chen X; Yu X; Wang Y; Zhu J; Gu J
Parasitol Res; 2017 Nov; 116(11):3027-3036. PubMed ID: 28965226
[TBL] [Abstract][Full Text] [Related]
17. Serum concentration of sFas and sFasL in healthy HBsAg carriers, chronic viral hepatitis B and C patients.
Lapinski TW; Kowalczuk O; Prokopowicz D; Chyczewski L
World J Gastroenterol; 2004 Dec; 10(24):3650-3. PubMed ID: 15534924
[TBL] [Abstract][Full Text] [Related]
18. Soluble Fas ligand and soluble Fas in ocular fluid of patients with uveitis.
Sugita S; Taguchi C; Takase H; Sagawa K; Sueda J; Fukushi K; Hikita N; Watanabe T; Itoh K; Mochizuki M
Br J Ophthalmol; 2000 Oct; 84(10):1130-4. PubMed ID: 11004098
[TBL] [Abstract][Full Text] [Related]
19. Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fas ligand system in patients with chronic heart failure.
Adamopoulos S; Parissis J; Karatzas D; Kroupis C; Georgiadis M; Karavolias G; Paraskevaidis J; Koniavitou K; Coats AJ; Kremastinos DT
J Am Coll Cardiol; 2002 Feb; 39(4):653-63. PubMed ID: 11849865
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of soluble Fas ligand in patients with silicosis.
Tomokuni A; Otsuki T; Isozaki Y; Kita S; Ueki H; Kusaka M; Kishimoto T; Ueki A
Clin Exp Immunol; 1999 Dec; 118(3):441-4. PubMed ID: 10594565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]